CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...